Ipsen: Cabometyx With Opdivo Demonstrated Continued Survival and Quality of Life Benefits

 

• Updated results to be presented at ASCO GU 2022 showed sustained efficacy and tumor shrinkage benefits with Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) compared to sunitinib¹
• People living with advanced renal cell carcinoma treated with the combination continued to report improvements in health-related quality of life²
• The safety profile at this longer follow-up in the CheckMate -9ER trial was consistent with that previously observed for Cabometyx and Opdivo¹

https://www.biospace.com/article/releases/ipsen-cabometyx-in-combination-with-opdivo-demonstrated-continued-survival-and-quality-of-life-benefits-with-over-two-years-of-follow-up-in-the-phase-iii-checkmate-9er-trial/